Resource impact statement
Cancer Drugs Fund technology
NICE has recommended pembrolizumab for use within the Cancer Drugs Fund as an option for untreated locally advanced or metastatic urothelial cancer when cisplatin-containing chemotherapy is unsuitable, in accordance with the criteria set out in the recommendations.
Pembrolizumab will be available to the NHS in line with the managed access agreement with NHS England. As part of this, NHS England and Merck Sharp and Dohme have a commercial access agreement that makes pembrolizumab available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence.
The resource impact of pembrolizumab will be covered by the Cancer Drugs Fund budget. The data collection period is expected to end in November 2019, when the results of the KEYNOTE-361 trial are available. The process for exiting the Cancer Drugs Fund will begin at this point and the review of the NICE guidance will start. The aim of the review is to decide whether or not the drug can be recommended for routine use. Further information can be found in NHS England’s Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) - A new deal for patients, taxpayers and industry.
The managed access agreement allows for up to 635 people with untreated locally advanced or metastatic urothelial cancer for whom cisplatin is unsuitable, to be treated each year with pembrolizumab.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: 13 June 2018